Holen Sie sich die Stockscreener-App
4.63
3.74%
-0.18
Schlusskurs vom Vortag:
$4.81
Offen:
$4.85
24-Stunden-Volumen:
1.43M
Relative Volume:
1.57
Marktkapitalisierung:
$279.94M
Einnahmen:
$217.78M
Nettoeinkommen (Verlust:
$-239.55M
KGV:
-1.1434
EPS:
-4.0492
Netto-Cashflow:
$-127.30M
1W Leistung:
-8.32%
1M Leistung:
-16.27%
6M Leistung:
-33.86%
1J Leistung:
-10.27%
1-Tages-Spanne:
$4.565
$4.85
1-Wochen-Bereich:
$4.565
$5.19
52-Wochen-Spanne:
$4.27
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.63 | 305.34M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It (NASDAQ:VNDA) - Seeking Alpha
Capitals Announce Fan Initiatives Surrounding Capitals Opening Night Presented by Vanda Pharmaceuticals - NHL.com
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug - Benzinga
Vanda Pharmaceuticals (VNDA) Reports Positive Phase III Results for HETLIOZ in DSWPD - GuruFocus
Vanda Pharmaceuticals says Phase III HETLIOZ study met sleep endpoint - Mugglehead Investment Magazine
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Why is Vanda Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Vanda Pharmaceuticals Announces Positive Phase III Results For Hetlioz®(Tasimelteon) In Delayed Sleep-Wake Phase Disorder - TradingView
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PR Newswire
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Teva, Apotex Don't Infringe Sleep Drug Patents, Judge Finds - Law360
Teva, Apotex Beat Vanda Patent Claims Over Hetlioz Sleep Drug - Bloomberg Law News
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Initiates Coverage On Oppenheimer -- Rating Outperform with $10.00 Price Target - GuruFocus
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Vanda Pharmaceuticals stock with outperform rating - Investing.com
Vanda Pharmaceuticals stock slips as 2025 loss widens - AD HOC NEWS
Vanda Pharmaceuticals at H.C. Wainwright conference: pipeline broadens By Investing.com - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus pivotal readouts, set up major growth opportunities ahead - TradingView
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA: BYSANTI and NEREUS launches, plus pipeline catalysts, set the stage for major revenue growth - TradingView
Vanda Pharmaceuticals at Cantor conference: psychiatry push takes center stage - Investing.com Canada
VNDA: BYSANTI and NEREUS launches, plus key phase III trials, set the stage for major revenue growth - TradingView
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals Inc. (VNDA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
DC’s Vanda Pharmaceuticals Wins EU Orphan Status for Its Rare Skin Disease Drug - BioBuzz
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences - StreetInsider
Four September conferences are planned for Vanda Pharmaceuticals. Two presentations may be accessed live. - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Peer Comparison – Compare with Others - valueresearchonline.com
Convert Vanda Pharmaceuticals Inc. (VNDA) to Canadian Dollar (CAD) - Crypto.com
Vanda Pharmaceuticals Mallorca Women's Championships 2026 Scores | Latest Scores & Live Updates – WTA Official - WTA Tennis
Millennium Management Expands Vanda Pharmaceuticals Stake Amid D - GuruFocus
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. - Sahm
Millennium reports 3.38M-share passive stake in Vanda (NASDAQ: VNDA) - Stock Titan
DC Circuit Partially Rejects Vanda’s Fight of Generic Sleep Drug - Bloomberg Law News
Vanda Pharmaceuticals Inc (VNDA) (Q2 2026) Earnings Call Highlig - GuruFocus
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
AIGH Capital Management LLC Purchases New Stake in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vanda Pharmaceuticals Inc-Aktie (VNDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):